CohBar, the California-headquartered biotech focused on mitochondria-based therapies, has hired Jordyn Tarazi as its new director of investor relations.
Tarazi joins from Fluent, a marketing company, where she worked for four years as director of IR. Prior to that, she worked at another biotech, OncoSec, as director of IR and corporate communications.
Earlier in her career, she worked in corporate access at HC Wainwright and as a roadshow co-ordinator for Rodman & Renshaw.
‘With her investment banking and biotechnology investor relations background, Jordyn will play a key role in raising awareness of our company as we continue to ramp up our efforts, both clinically and preclinically, to develop novel therapeutics for chronic diseases,’ says Steven Engle, CEO of CohBar, in a company statement.
Nasdaq-listed CohBar, which went public five years ago, is developing mitochondria-based therapies to treat age-related diseases. It currently has a treatment at clinical-trial stage focused on non-alcoholic steatohepatitis and obesity.
Commenting in the statement, Tarazi says she looks forward to ‘building a world-class investor relations program and working with the team to communicate to key stakeholders the evolving story of CohBar’s unique mitochondrial peptide platform as a source for potential novel therapeutics.’
